Blocking of NF-kB activity using the IMD inhibitor in combination with doxorubicin significantly decreased tumor cells viability and stem cells activity in tumorsphere assays, thus phenocopying the effects of the Dll1-blocking antibody. This evidence concerns the gene NFKB1 and neoplasm.